← Back
Apellis Pharmaceuticals
APLS
$41.03
+0.00% on May 15
No insider bought Apellis Pharmaceuticals stock in the last year. They sold it 27 times, $2.79 million in all.
No insider trades or company news in this range.
Shares borrowed and sold by investors who expect the price to drop.
Company insiders
In the last year, eight insiders sold Apellis Pharmaceuticals stock and none bought. None of the 27 sales is marked on its filing as planned in advance; all by company executives. The biggest seller was Cedric Francois, Chief Executive Officer.
All reports
Every insider trade and SEC report we hold for Apellis Pharmaceuticals.
Newest first
ReportedTradeInsiderOf their holdingShares @ priceValue
Feb 13SoldMark Jeffrey DeLongFeb 13 · Traded Feb 11 · Chief Business & Strat Officer368 @ $22.15$8.2K
Jan 23SoldJames George ChopasJan 23 · Traded Jan 22 · VP/Chief Accounting Officer2,064 @ $21.77$44.9K
Jan 23SoldMark Jeffrey DeLongJan 23 · Traded Jan 22 · Chief Business & Strat Officer3,371 @ $21.77$73.4K
41 more with Pro →Analysts, earnings and news
Analysts' price target
$40.92 average
13 analysts
Analysts' opinions, which tend to run optimistic. Not our forecast or advice.
Profit vs what was expected
3 of 4 quarters above
Q1 '26$0.15 a share+$0.51
Q4 '25−$0.47 a share−$0.08
Q3 '25$1.67 a share+$0.73
Q2 '25−$0.33 a share+$0.14